Cancer Immunotherapy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Cancer Immunotherapy stocks.

Cancer Immunotherapy Stocks Recent News

Date Stock Title
May 24 IOVA Iovance Biotherapeutics to Present at Upcoming Conferences and Events
May 24 IOVA Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
May 24 HOWL Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
May 24 EVAX Evaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination Treatment
May 23 HOWL Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
May 23 IOVA Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
May 23 EVAX Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
May 23 NBTX NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
May 23 NBTX Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript
May 22 IMNM Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying
May 22 IOVA Bull Market Buys: 2 Growth Stocks to Own for the Long Run
May 22 NBTX Nanobiotix reports Q1 results
May 22 NBTX NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
May 21 IMNM Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares
May 21 NBTX Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
May 20 IMNM Immunome Announces Completion of Purchase of Assets from Atreca
Cancer Immunotherapy

Cancer immunotherapy (sometimes called immuno-oncology) is the artificial stimulation of the immune system to treat cancer, improving on the system's natural ability to fight cancer. It is an application of the fundamental research of cancer immunology and a growing subspecialty of oncology. It exploits the fact that cancer cells often have tumor antigens, molecules on their surface that can be detected by the antibody proteins of the immune system, binding to them. The tumor antigens are often proteins or other macromolecules (e.g. carbohydrates). Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill.

Browse All Tags